EUVIMEDEUVIMED entdecken
Crossref

Outcomes following proton therapy for pediatric esthesioneuroblastoma

Nicolette R Drescher, Daniel J Indelicato iD, Roi Dagan, Julie A Bradley, Adam L Holtzman, Raymond B Mailhot Vega, Philipp R Aldana, Eric S Sandler, Christopher G Morris, William M Mendenhall

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Nicolette R Drescher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Proton Therapy, Esthesioneuroblastoma, Olfactory, Nose Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric esthesioneuroblastoma (EN) can infiltrate skull base anatomy, presenting challenges due to high radiation doses and pediatric tissue sensitivity. This study reports outcomes of pediatric EN treated with proton radiotherapy (PT). Procedure Using an IRB‐approved prospective outcomes registry, we evaluated patient, tumor, and treatment‐related variables impacting disease control and toxicity in pediatric nonmetastatic EN treated with modern multimodality therapy, including PT.

Results

Fifteen consecutive patients (median age 16) comprising Kadish stage B ( n = 2), C ( n = 9), and D ( n = 4) tumors were assessed, including six with intracranial involvement, four with cranial nerve deficits, and four with cervical lymphadenopathy. Before radiation, two had subtotal and 13 had gross total resections (endoscopic or craniofacial). Two underwent neck dissection. Eleven received chemotherapy before radiation ( n = 5), concurrent with radiation ( n = 4), or both ( n = 2). Median total radiation dose (primary site) was 66 Gy/CGE for gross disease and 54 Gy/CGE (cobalt Gray equivalent) for microscopic disease. Median follow‐up was 4.8 years. No patients were lost to follow‐up. Five‐year disease‐free and overall survival rates were 86% (no local or regional recurrences). Two patients developed vertebral metastases and died. Two required a temporary feeding tube for oral mucositis/dysphagia. Late toxicities included symptomatic retinopathy, major reconstructive surgery, cataracts, chronic otitis media, chronic keratoconjunctivitis, hypothyroidism, and in‐field basal cell skin cancer.

Conclusions

A multimodality approach for pediatric EN results in excellent local control. Despite the moderate‐dose PT, serious radiation toxicity was observed; further dose and target volume reductions may benefit select patients. Longer follow‐up and comparative data from modern photon series are necessary to fully characterize any relative PT advantage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton TherapyEsthesioneuroblastoma, OlfactoryNose NeoplasmsHumansChildAdolescentProspective StudiesNasal CavityRadiotherapy Dosage

Stichwörter der Autor:innen

esthesioneuroblastomaoverall survivalpediatricpeds ENproton

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurosurgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
  • Department of Pediatrics, Nemours Children's Specialty Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Daniel J Indelicato

Förderung

  • NCATS NIH HHS

Zitieren

APA

Drescher, N. R., Indelicato, D. J., Dagan, R., Bradley, J. A., Holtzman, A. L., Mailhot Vega, R. B., Aldana, P. R., Sandler, E. S., Morris, C. G., & Mendenhall, W. M. (2024). Outcomes following proton therapy for pediatric esthesioneuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30793

Vancouver

Drescher NR, Indelicato DJ, Dagan R, Bradley JA, Holtzman AL, Mailhot Vega RB, et al. Outcomes following proton therapy for pediatric esthesioneuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30793

BibTeX
@article{Drescher2024,
  author = {Drescher, Nicolette R and Indelicato, Daniel J and Dagan, Roi and Bradley, Julie A and Holtzman, Adam L and Mailhot Vega, Raymond B and Aldana, Philipp R and Sandler, Eric S and Morris, Christopher G and Mendenhall, William M},
  title = {Outcomes following proton therapy for pediatric esthesioneuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30793}
}
Kostenlos starten →